Format

Send to

Choose Destination
Oncotarget. 2017 Aug 24;8(44):77309-77316. doi: 10.18632/oncotarget.20468. eCollection 2017 Sep 29.

Sirtuin 7: a new marker of aggressiveness in prostate cancer.

Author information

1
Université Côte d'Azur, C3M-Inserm U1065, Nice, France.
2
Urology Department, CHU Nice, Nice, France.
3
Pathology Department, CHU Nice, Nice, France.

Abstract

Predictive biomarkers for advanced prostate cancer (PCa) are still missing. The sirtuin 7 (SIRT7) has been linked to tumorogenesis but its role in prostate cancer is poorly documented. To determine if SIRT7 can be a biomarker for aggressive prostate cancer and plays a role in PCa aggressiveness. We analyzed the expression of SIRT7 by immunohistochemistry in 57 patients comparing healthy with adjacent cancer tissue. SIRT7 levels were significantly elevated in tumors and its expression was positively associated with the grade. We also demonstrated that the knock down of SIRT7 decreased the migration of DU145 and PC3 cells (two androgen-independent prostate cancer cell lines) whereas the overexpression of the native protein but not the mutated form increased the cell migration and the invasion of the poorly aggressive prostate cancer cell line LNCaP. Finally, we also showed that SIRT7 overexpression induced the resistance to docetaxel. Our results demonstrate that SIRT7 promotes prostate cancer cell aggressiveness and chemoresistance and suggest that SIRT7 is a good predictive biomarker of PCa aggressiveness.

KEYWORDS:

cell migration; metabolism; metastasis; prostate cancer; sirtuins

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare no conflicts of interest.

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center